摘要 |
<p>This invention relates to a novel crystalline polymorphic form of irinotecan hydrochloride. A process for preparing this novel polymorphic form, pharmaceutical compositions comprising it as an active ingredient and the use of the same and its pharmaceutical compositions as a therapeutic agent is also within the scope of the present invention.</p> |